Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BAX 326 perioperative efficacy and safety study in hemophilia B
2011-000413-39Phase 3Completed
- Sponsor
- Baxter International Inc.
- Start
- Jul 2011
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of recombinant human Factor IX in hemophilia B (HB), sponsored by Baxter International Inc. Primary endpoint: Hemostatic efficacy. Started Jul 2011; status: completed.
02
Drugs
recombinant human Factor IX
03
Conditions
hemophilia B (HB)
Beyond the preview
Go deeper on 2011-000413-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-000413-39.